CRISPR Therapeutics AG (CRSP)
CRSP Stock Price Chart
Explore CRISPR Therapeutics AG interactive price chart. Choose custom timeframes to analyze CRSP price movements and trends.
CRSP Company Profile
Discover essential business fundamentals and corporate details for CRISPR Therapeutics AG (CRSP) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
19 Oct 2016
Employees
393.00
Website
https://www.crisprtx.comCEO
Samarth Kulkarni
Description
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
CRSP Financial Timeline
Browse a chronological timeline of CRISPR Therapeutics AG corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 3 Aug 2026
EPS estimate is -$1.20, while revenue estimate is $7.45m.
Earnings released on 4 May 2026
EPS came in at -$1.28 falling short of the estimated -$1.19 by -7.60%, while revenue for the quarter reached $1.46m , missing expectations by -75.96%.
Earnings released on 12 Feb 2026
EPS came in at -$1.37 falling short of the estimated -$1.15 by -19.13%, while revenue for the quarter reached $864.00k , missing expectations by -81.69%.
Earnings released on 10 Nov 2025
EPS came in at -$1.17 surpassing the estimated -$1.26 by +7.14%, while revenue for the quarter reached $889.00k , missing expectations by -90.25%.
Earnings released on 4 Aug 2025
EPS came in at -$1.29 surpassing the estimated -$1.47 by +12.24%, while revenue for the quarter reached $892.00k , missing expectations by -90.55%.
Earnings released on 6 May 2025
EPS came in at -$1.58 falling short of the estimated -$1.27 by -24.41%, while revenue for the quarter reached $865.00k , missing expectations by -85.50%.
Earnings released on 11 Feb 2025
EPS came in at -$0.44 surpassing the estimated -$1.15 by +61.74%, while revenue for the quarter reached $35.00m , beating expectations by +334.51%.
Earnings released on 5 Nov 2024
EPS came in at -$1.01 surpassing the estimated -$1.33 by +24.06%, while revenue for the quarter reached $602.00k , missing expectations by -92.18%.
Earnings released on 5 Aug 2024
EPS came in at -$1.49 falling short of the estimated -$1.37 by -8.76%, while revenue for the quarter reached $517.00k , missing expectations by -96.88%.
Earnings released on 8 May 2024
EPS came in at -$1.43 surpassing the estimated -$1.63 by +12.27%, while revenue for the quarter reached $504.00k , missing expectations by -85.76%.
Earnings released on 21 Feb 2024
EPS came in at $1.10 surpassing the estimated -$0.07 by +1.67k%, while revenue for the quarter reached $200.00m , beating expectations by +611.49%.
Earnings released on 6 Nov 2023
EPS came in at -$1.41 surpassing the estimated -$1.98 by +28.79%.
Earnings released on 7 Aug 2023
EPS came in at -$0.98 surpassing the estimated -$2.18 by +55.05%, while revenue for the quarter reached $70.00m , beating expectations by +3.99k%.
Earnings released on 8 May 2023
EPS came in at -$0.67 surpassing the estimated -$1.67 by +59.88%, while revenue for the quarter reached $100.00m , beating expectations by +5.75k%.
Earnings released on 21 Feb 2023
EPS came in at -$1.41 surpassing the estimated -$2.32 by +39.22%, while revenue for the quarter reached $6.00k , missing expectations by -73.89%.
Earnings released on 1 Nov 2022
EPS came in at -$2.24 surpassing the estimated -$2.30 by +2.61%, while revenue for the quarter reached $94.00k , missing expectations by -94.91%.
Earnings released on 8 Aug 2022
EPS came in at -$2.40 falling short of the estimated -$2.23 by -7.62%, while revenue for the quarter reached $158.00k , missing expectations by -92.86%.
Earnings released on 9 May 2022
EPS came in at -$2.32 falling short of the estimated -$1.91 by -21.47%, while revenue for the quarter reached $178.00k , missing expectations by -93.64%.
Earnings released on 15 Feb 2022
EPS came in at -$1.84 falling short of the estimated -$1.74 by -5.75%, while revenue for the quarter reached $12.35m , beating expectations by +465.05%.
Earnings released on 3 Nov 2021
EPS came in at -$1.67 surpassing the estimated -$1.69 by +1.18%, while revenue for the quarter reached $329.00k , missing expectations by -60.54%.
Earnings released on 29 Jul 2021
EPS came in at $9.44 surpassing the estimated $3.52 by +168.18%, while revenue for the quarter reached $900.20m , beating expectations by +6.41%.
CRSP Stock Performance
Access detailed CRSP performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
